Population
Patients and animal models with cardiac diseases, particularly cardiomyopathy and heart failure
Design
Review
Authors
Loading...
Bezafibrate may merit targeted trials in metabolic cardiomyopathy; leaves open whether lipid normalization improves clinical outcomes.
PPAR agonists, particularly bezafibrate, show potential as therapeutic agents to protect the heart from energy deprivation and attenuate cardiomyopathy and heart failure.
Khuchua et al. (2018) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: